Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jul;72(1):65–71. doi: 10.1038/bjc.1995.278

An evaluation of hepatic extraction and clearance of doxorubicin.

D A August 1, N Verma 1, M A Vaertan 1, R Shah 1, D E Brenner 1
PMCID: PMC2034109  PMID: 7599068

Abstract

A swine model was developed to study quantitatively the pharmacokinetics of hepatic extraction and clearance of doxorubicin (DOX). Systemic and hepatic artery infusions of DOX (0.5-9 mg kg-1) were administered to 34 pigs. Pharmacokinetic analysis was simplified by use of a double-balloon catheter in the inferior vena cava to collect hepatic venous effluent. During hepatic artery infusion only, DOX in hepatic venous blood was extracted using activated carbon filters to prevent drug recirculation. Hepatic extraction and clearance of DOX were independent of dose and route of administration. Extraction ratios varied from 0.75 to 0.91 during hepatic artery infusion and from 0.50 to 0.72 during systemic infusion. Clearance results were analogous. After cessation of drug infusions, hepatic extraction and clearance of DOX was negative, suggesting that the liver serves as a drug reservoir during DOX infusion and subsequently is a net source of unmetabolised drug. Liver extraction and clearance of DOX in pigs are substantial. During either systemic or hepatic artery infusion of DOX, the liver serves as a drug reservoir. Subsequent mobilisation of this hepatic pool of DOX may cause prolonged systemic exposure to drug.

Full text

PDF
65

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackland S. P., Ratain M. J., Vogelzang N. J., Choi K. E., Ruane M., Sinkule J. A. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989 Apr;45(4):340–347. doi: 10.1038/clpt.1989.39. [DOI] [PubMed] [Google Scholar]
  2. Arvidsson D., Svensson H., Haglund U. Laser-Doppler flowmetry for estimating liver blood flow. Am J Physiol. 1988 Apr;254(4 Pt 1):G471–G476. doi: 10.1152/ajpgi.1988.254.4.G471. [DOI] [PubMed] [Google Scholar]
  3. August D. A., Verma N., Andrews J. C., Vaerten M. A., Brenner D. E. Hepatic artery infusion of doxorubicin with hepatic venous drug extraction. J Surg Res. 1994 Jun;56(6):611–619. doi: 10.1006/jsre.1994.1097. [DOI] [PubMed] [Google Scholar]
  4. Bachur N. R., Gordon S. L., Gee M. V., Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A. 1979 Feb;76(2):954–957. doi: 10.1073/pnas.76.2.954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bachur N. R., Hildebrand R. C., Jaenke R. S. Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther. 1974 Nov;191(2):331–340. [PubMed] [Google Scholar]
  6. Ballet F., Barbare J. C., Poupon R. Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1984 Jun;20(6):761–764. doi: 10.1016/0277-5379(84)90213-x. [DOI] [PubMed] [Google Scholar]
  7. Benjamin R. S., Riggs C. E., Jr, Bachur N. R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977 May;37(5):1416–1420. [PubMed] [Google Scholar]
  8. Benjamin R. S., Wiernik P. H., Bachur N. R. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer. 1974 Jan;33(1):19–27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  9. Brenner D. E., Anthony L. B., Halter S., Harris N. L., Collins J. C., Hande K. R. Effect of allyl alcohol-induced sublethal hepatic damage upon doxorubicin metabolism and toxicity in the rabbit. Cancer Res. 1987 Jun 15;47(12):3259–3265. [PubMed] [Google Scholar]
  10. Brenner D. E. Approaches to the problem of individual doxorubicin dosing schedules. Pathol Biol (Paris) 1987 Jan;35(1):31–39. [PubMed] [Google Scholar]
  11. Brenner D. E., Galloway S., Cooper J., Noone R., Hande K. R. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Cancer Chemother Pharmacol. 1985;14(2):139–145. doi: 10.1007/BF00434353. [DOI] [PubMed] [Google Scholar]
  12. Brenner D. E., Wiernik P. H., Wesley M., Bachur N. R. Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer. 1984 Mar 1;53(5):1042–1048. doi: 10.1002/1097-0142(19840301)53:5<1042::aid-cncr2820530505>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  13. Carr B. I., Iwatsuki S., Starzl T. E., Selby R., Madariaga J. Regional cancer chemotherapy for advanced stage hepatocellular carcinoma. J Surg Oncol Suppl. 1993;3:100–103. doi: 10.1002/jso.2930530528. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Chan K. K., Chlebowski R. T., Tong M., Chen H. S., Gross J. F., Bateman J. R. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res. 1980 Apr;40(4):1263–1268. [PubMed] [Google Scholar]
  15. Di Fronzo G., Gambetta R. A., Lenaz L. Distribution and metabolism of adriamycin in mice. Comparison with daunomycin. Rev Eur Etud Clin Biol. 1971 Jun-Jul;16(6):572–576. [PubMed] [Google Scholar]
  16. Eichholtz-Wirth H. Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. Br J Cancer. 1980 Jun;41(6):886–891. doi: 10.1038/bjc.1980.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Felsted R. L., Bachur N. R. Mammalian carbonyl reductases. Drug Metab Rev. 1980;11(1):1–60. doi: 10.3109/03602538008994021. [DOI] [PubMed] [Google Scholar]
  18. Garnick M. B., Ensminger W. D., Israel M. A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res. 1979 Oct;39(10):4105–4110. [PubMed] [Google Scholar]
  19. Gelman S., Dillard E., Bradley E. L., Jr Hepatic circulation during surgical stress and anesthesia with halothane, isoflurane, or fentanyl. Anesth Analg. 1987 Oct;66(10):936–943. [PubMed] [Google Scholar]
  20. Greene R. F., Collins J. M., Jenkins J. F., Speyer J. L., Myers C. E. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 1983 Jul;43(7):3417–3421. [PubMed] [Google Scholar]
  21. Gutiérrez P. L., Gee M. V., Bachur N. R. Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68–75. doi: 10.1016/0003-9861(83)90572-6. [DOI] [PubMed] [Google Scholar]
  22. KESTENS P. J., FARRELLY J. A., MCDERMOTT W. V., Jr A technique of isolation and perfusion of the canine liver. J Surg Res. 1961 May;1:58–63. doi: 10.1016/s0022-4804(61)80023-1. [DOI] [PubMed] [Google Scholar]
  23. Kanematsu T., Furuta T., Takenaka K., Matsumata T., Yoshida Y., Nishizaki T., Hasuo K., Sugimachi K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989 Jul;10(1):98–102. doi: 10.1002/hep.1840100119. [DOI] [PubMed] [Google Scholar]
  24. Kaye S. B., Cummings J., Kerr D. J. How much does liver disease affect the pharmacokinetics of adriamycin? Eur J Cancer Clin Oncol. 1985 Aug;21(8):893–895. doi: 10.1016/0277-5379(85)90103-8. [DOI] [PubMed] [Google Scholar]
  25. Kobayashi H., Hidaka H., Kajiya Y., Tanoue P., Inoue H., Ikeda K., Nakajo M., Shinohara S. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn (Stockh) 1986 Mar-Apr;27(2):139–147. doi: 10.1177/028418518602700203. [DOI] [PubMed] [Google Scholar]
  26. Ku Y., Saitoh M., Nishiyama H., Fujiwara S., Iwasaki T., Tominaga M., Maekawa Y., Ohyanagi H., Saitoh Y. Extracorporeal removal of anticancer drugs in hepatic artery infusion: the effect of direct hemoperfusion combined with venovenous bypass. Surgery. 1990 Mar;107(3):273–281. [PubMed] [Google Scholar]
  27. Legha S. S., Benjamin R. S., Mackay B., Ewer M., Wallace S., Valdivieso M., Rasmussen S. L., Blumenschein G. R., Freireich E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133–139. doi: 10.7326/0003-4819-96-2-133. [DOI] [PubMed] [Google Scholar]
  28. Martínková J., Bulas J., Krejcí V., Hartman M., Tilser I., Hůlek P. A study of the inhibition of adrenaline-induced vasoconstriction in the isolated perfused liver of rabbit. Hepatology. 1990 Nov;12(5):1157–1165. doi: 10.1002/hep.1840120514. [DOI] [PubMed] [Google Scholar]
  29. Moertel C. G. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987 Oct;5(10):1502–1522. doi: 10.1200/JCO.1987.5.10.1502. [DOI] [PubMed] [Google Scholar]
  30. Munck J. N., Riggi M., Rougier P., Chabot G. G., Ramirez L. H., Zhao Z., Bognel C., Ardouin P., Herait P., Gouyette A. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res. 1993 Apr 1;53(7):1550–1554. [PubMed] [Google Scholar]
  31. Oki T., Komiyama T., Tone H., Inui T., Takeuchi T., Umezawa H. Reductive cleavage of anthracycline glycosides by microsomal NADPH-cytochrome C reductase. J Antibiot (Tokyo) 1977 Jul;30(7):613–615. doi: 10.7164/antibiotics.30.613. [DOI] [PubMed] [Google Scholar]
  32. Pelletier G., Roche A., Ink O., Anciaux M. L., Derhy S., Rougier P., Lenoir C., Attali P., Etienne J. P. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990 Sep;11(2):181–184. doi: 10.1016/0168-8278(90)90110-d. [DOI] [PubMed] [Google Scholar]
  33. Preiss R., Matthias M., Sohr R., Brockmann B., Hüller H. Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. J Cancer Res Clin Oncol. 1987;113(6):593–598. doi: 10.1007/BF00390872. [DOI] [PubMed] [Google Scholar]
  34. Ruszniewski P., Rougier P., Roche A., Legmann P., Sibert A., Hochlaf S., Ychou M., Mignon M. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993 Apr 15;71(8):2624–2630. doi: 10.1002/1097-0142(19930415)71:8<2624::aid-cncr2820710830>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  35. Schwemmle K., Aigner K. Requirements and results of liver perfusion. Recent Results Cancer Res. 1986;100:229–233. doi: 10.1007/978-3-642-82635-1_29. [DOI] [PubMed] [Google Scholar]
  36. Sindelar W. F. Isolation-perfusion of the liver with 5-fluorouracil. Ann Surg. 1985 Mar;201(3):337–343. doi: 10.1097/00000658-198503000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Skibba J. L., Almagro U. A., Condon R. E., Petroff R. J., Jr A technique for isolation perfusion of the canine liver with survival. J Surg Res. 1983 Feb;34(2):123–132. doi: 10.1016/0022-4804(83)90051-3. [DOI] [PubMed] [Google Scholar]
  38. Skibba J. L., Condon R. E. Hyperthermic isolation-perfusion in vivo of the canine liver. Cancer. 1983 Apr 1;51(7):1303–1309. doi: 10.1002/1097-0142(19830401)51:7<1303::aid-cncr2820510721>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  39. Takanashi S., Bachur N. R. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos. 1976 Jan-Feb;4(1):79–87. [PubMed] [Google Scholar]
  40. Terasaki T., Iga T., Sugiyama Y., Hanano M. Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant. J Pharm Pharmacol. 1982 Sep;34(9):597–600. doi: 10.1111/j.2042-7158.1982.tb04804.x. [DOI] [PubMed] [Google Scholar]
  41. de Brauw L. M., Marinelli A., van de Velde C. J., Hermans J., Tjaden U. R., Erkelens C., de Bruijn E. A. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. Cancer Res. 1991 Mar 15;51(6):1694–1700. [PubMed] [Google Scholar]
  42. van de Velde C. J., Kothuis B. J., Barenbrug H. W., Jongejan N., Runia R. D., de Brauw L. M., Zwaveling A. A successful technique of in vivo isolated liver perfusion in pigs. J Surg Res. 1986 Dec;41(6):593–599. doi: 10.1016/0022-4804(86)90084-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES